Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 3/2012

01.03.2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement

verfasst von: Brian M. Berger, James A. Phillips

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Compare outcomes with vaginal gel versus intramuscular progesterone replacement in donor oocyte recipients.

Methods

A single-center retrospective analysis (January 2004–December 2006) evaluated pregnancy outcomes (serum human chorionic gonadotropin, implantation, clinical pregnancy, delivery, total pregnancy loss rates) for 225 recipients of embryos from donor (aged <32 years) oocytes. Vaginal progesterone gel (Crinone® 8%; 90 mg twice daily; n = 105) or intramuscular progesterone (50 mg once daily; n = 120) was started the afternoon of oocyte retrieval and continued until a negative pregnancy test or 10 weeks’ gestation.

Results

There were no statistically significant differences between groups for the five pregnancy outcomes; numerical results favored vaginal progesterone in all cases. Confidence intervals showed vaginal gel was within, or <1% from, a noninferiority limit of 10% versus intramuscular progesterone for four of five pregnancy outcomes.

Conclusions

Pregnancy outcomes were comparable for progesterone replacement with vaginal gel and intramuscular progesterone in an oocyte donation program.
Literatur
1.
2.
Zurück zum Zitat Dey SK, Davis DL, Hersey RM, Weisz J, Johnson DC, Pakrasi PL. Physiological aspects of blastocyst uterine interaction. J Biosci. 1984;6 Suppl 2:23–31.CrossRef Dey SK, Davis DL, Hersey RM, Weisz J, Johnson DC, Pakrasi PL. Physiological aspects of blastocyst uterine interaction. J Biosci. 1984;6 Suppl 2:23–31.CrossRef
3.
Zurück zum Zitat Emiliani S, Delbaere A, Devreker F, Englert Y. Embryo-maternal interactive factors regulating the implantation process: implications in assisted reproduction. Reprod Biomed. 2005;Online 10:527–40. Emiliani S, Delbaere A, Devreker F, Englert Y. Embryo-maternal interactive factors regulating the implantation process: implications in assisted reproduction. Reprod Biomed. 2005;Online 10:527–40.
4.
Zurück zum Zitat de Ziegler D, Fanchin R, Massonneau M, Bergeron C, Frydman R, Bouchard P. Hormonal control of endometrial receptivity. The egg donation model and controlled ovarian hyperstimulation. Ann NY Acad Sci. 1994;734:209–20.PubMedCrossRef de Ziegler D, Fanchin R, Massonneau M, Bergeron C, Frydman R, Bouchard P. Hormonal control of endometrial receptivity. The egg donation model and controlled ovarian hyperstimulation. Ann NY Acad Sci. 1994;734:209–20.PubMedCrossRef
5.
Zurück zum Zitat Punyadeera C, Verbost P, Groothuis P. Oestrogen and progestin responses in human endometrium. J Steroid Biochem Mol Biol. 2003;84:393–410.PubMedCrossRef Punyadeera C, Verbost P, Groothuis P. Oestrogen and progestin responses in human endometrium. J Steroid Biochem Mol Biol. 2003;84:393–410.PubMedCrossRef
6.
Zurück zum Zitat Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotropin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999;14:1944–8.PubMedCrossRef Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotropin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999;14:1944–8.PubMedCrossRef
7.
Zurück zum Zitat Licciardi FL, Kwiatkowski A, Noyes NL, Berkley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril. 1999;71:614–8.PubMedCrossRef Licciardi FL, Kwiatkowski A, Noyes NL, Berkley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril. 1999;71:614–8.PubMedCrossRef
8.
Zurück zum Zitat Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–9.PubMedCrossRef Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–9.PubMedCrossRef
9.
Zurück zum Zitat Ciccinelli E, de Ziegler D, Bulletti C, Matteo MG, Schronauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6.CrossRef Ciccinelli E, de Ziegler D, Bulletti C, Matteo MG, Schronauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–6.CrossRef
10.
Zurück zum Zitat Levine H. Luteal support from the vaginal progesterone (P) gel Crinone 8%: preliminary results of multicenter trial show higher pregnancy rates than historical controls. J Soc Gynecol Investig. 2000;7 Suppl 571:203A. Levine H. Luteal support from the vaginal progesterone (P) gel Crinone 8%: preliminary results of multicenter trial show higher pregnancy rates than historical controls. J Soc Gynecol Investig. 2000;7 Suppl 571:203A.
11.
Zurück zum Zitat Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–8.PubMedCrossRef Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–8.PubMedCrossRef
12.
Zurück zum Zitat Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89:485–7.PubMedCrossRef Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89:485–7.PubMedCrossRef
13.
Zurück zum Zitat Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–7.PubMedCrossRef Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–7.PubMedCrossRef
14.
Zurück zum Zitat Anserini M, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni R. Luteal phase support in assisted reproduction cycles using either vaginal (Crinone 8) or systemic (Prontogest) progesterone: results of a prospective, randomized study. Minerva Ginecol. 2001;53:297–301.PubMed Anserini M, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni R. Luteal phase support in assisted reproduction cycles using either vaginal (Crinone 8) or systemic (Prontogest) progesterone: results of a prospective, randomized study. Minerva Ginecol. 2001;53:297–301.PubMed
15.
Zurück zum Zitat Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9.PubMedCrossRef Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–9.PubMedCrossRef
16.
Zurück zum Zitat Ottoson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol. 1984;91:1111–9.PubMedCrossRef Ottoson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol. 1984;91:1111–9.PubMedCrossRef
17.
Zurück zum Zitat Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999;44:141–7.PubMed Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999;44:141–7.PubMed
18.
Zurück zum Zitat Gibbons WE, Toner JP, Hammacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101.PubMedCrossRef Gibbons WE, Toner JP, Hammacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101.PubMedCrossRef
19.
Zurück zum Zitat Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates [Abstract P-363]. Fertil Steril. 2000;74 Suppl 1:S209.CrossRef Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates [Abstract P-363]. Fertil Steril. 2000;74 Suppl 1:S209.CrossRef
20.
Zurück zum Zitat Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984;307:174–5.PubMedCrossRef Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984;307:174–5.PubMedCrossRef
21.
Zurück zum Zitat Crinone® 4% and Crinone® 8% (progesterone gel) [prescribing information], Livingston, NJ: Columbia Laboratories, Inc. 2009. Crinone® 4% and Crinone® 8% (progesterone gel) [prescribing information], Livingston, NJ: Columbia Laboratories, Inc. 2009.
22.
Zurück zum Zitat Witmyer J, Wang S, Alper M, Powers R. HIP embryos: effective criteria for high pregnancy rates with low high order multiples. Fertil Steril. 2003;80:S139–40.CrossRef Witmyer J, Wang S, Alper M, Powers R. HIP embryos: effective criteria for high pregnancy rates with low high order multiples. Fertil Steril. 2003;80:S139–40.CrossRef
23.
Zurück zum Zitat Greenblatt DJ, Allen MD. Intramuscular injection site complications. JAMA. 1978;49:536. Greenblatt DJ, Allen MD. Intramuscular injection site complications. JAMA. 1978;49:536.
24.
Zurück zum Zitat Al-Shawaf T, Zosmer A, Dirnfeld M, Grudzinkas G. Safety of drugs used in assisted reproduction techniques. Drug Saf. 2005;28:513–28.PubMedCrossRef Al-Shawaf T, Zosmer A, Dirnfeld M, Grudzinkas G. Safety of drugs used in assisted reproduction techniques. Drug Saf. 2005;28:513–28.PubMedCrossRef
25.
Zurück zum Zitat Penzias A, Alper M. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed. 2003;Online 6:187–295. Penzias A, Alper M. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed. 2003;Online 6:187–295.
26.
Zurück zum Zitat Phipps WR, Benson CB, McShane PM. Severe thigh myositis following intramuscular progesterone injection in an in vitro fertilization patient. Fertil Steril. 1988;49:536–7.PubMed Phipps WR, Benson CB, McShane PM. Severe thigh myositis following intramuscular progesterone injection in an in vitro fertilization patient. Fertil Steril. 1988;49:536–7.PubMed
27.
Zurück zum Zitat Phy J. Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer. Fertil Steril. 2003;80:1272–5.PubMedCrossRef Phy J. Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer. Fertil Steril. 2003;80:1272–5.PubMedCrossRef
28.
Zurück zum Zitat Kline DG, Kim D, Midha R, Harsh C, Tiel R. Management and results of sciatic nerve injuries: a 24-year experience. J Neurosurg. 1998;89:13–23.PubMedCrossRef Kline DG, Kim D, Midha R, Harsh C, Tiel R. Management and results of sciatic nerve injuries: a 24-year experience. J Neurosurg. 1998;89:13–23.PubMedCrossRef
29.
Zurück zum Zitat Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular injection of progesterone as luteal phase support after IVF: case report. Hum Reprod. 2004;19:1806–10.PubMedCrossRef Bouckaert Y, Robert F, Englert Y, De Backer D, De Vuyst P, Delbaere A. Acute eosinophilic pneumonia associated with intramuscular injection of progesterone as luteal phase support after IVF: case report. Hum Reprod. 2004;19:1806–10.PubMedCrossRef
30.
Zurück zum Zitat Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization. Ann Emerg Med. 2006;47:472–5.PubMedCrossRef Veysman B, Vlahos I, Oshva L. Pneumonitis and eosinophilia after in vitro fertilization. Ann Emerg Med. 2006;47:472–5.PubMedCrossRef
Metadaten
Titel
Pregnancy outcomes in oocyte donation recipients: vaginal gel versus intramuscular injection progesterone replacement
verfasst von
Brian M. Berger
James A. Phillips
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 3/2012
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-011-9691-9

Weitere Artikel der Ausgabe 3/2012

Journal of Assisted Reproduction and Genetics 3/2012 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.